Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor-intrinsic resistance mechanism is cross-talk between the EGFR and hepatocyte growth factor (HGF)/cMet pathways. Dual pathway inhibit...

Full description

Bibliographic Details
Main Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
HNSCC
cetuximab
ficlatuzumab
EGFR
HGF
cMet
Online Access:https://www.mdpi.com/2072-6694/12/6/1537

Internet

https://www.mdpi.com/2072-6694/12/6/1537

Similar Items